---
title: The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
nct_id: NCT00044148
overall_status: COMPLETED
phase: PHASE2
sponsor: Chromaderm, Inc.
study_type: INTERVENTIONAL
primary_condition: Diabetic Nephropathy
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00044148.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00044148"
ct_last_update_post_date: 2017-02-01
last_seen_at: "2026-05-12T06:44:18.484Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

**Official Title:** The Effect of LY333531 on Albuminuria in Patients With Type 2 Diabetes A Pilot Clinical Trial

**NCT ID:** [NCT00044148](https://clinicaltrials.gov/study/NCT00044148)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Lead Sponsor:** Chromaderm, Inc.
- **Conditions:** Diabetic Nephropathy
- **Start Date:** 2002-07-16
- **Completion Date:** 2004-04-28
- **CT.gov Last Update:** 2017-02-01

## Brief Summary

The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.

## Eligibility

- **Minimum age:** 30 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Type 2 diabetes mellitus
* Greater than or equal to 30 years of age
* Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier.

Exclusion Criteria:

* Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females
* B/P greater than 150 systolic and greater than 90 diastolic
* Hemoglobin Alc greater than 11%
* Liver Function Tests 2 times upper limit of normal
* Poor medical or psychiatric risk.
```

## Interventions

- **LY333531** (DRUG)

## Locations (15)

- La Jolla, California, United States
- Walnut Creek, California, United States
- Jacksonville, Florida, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- Lexington, Kentucky, United States
- Baltimore, Maryland, United States
- Waltham, Massachusetts, United States
- Minneapolis, Minnesota, United States
- St Louis, Missouri, United States
- New York, New York, United States
- Greenville, North Carolina, United States
- Dallas, Texas, United States
- Seattle, Washington, United States
- Spokane, Washington, United States

## Recent Field Changes (last 30 days)

- `locations.|new york|new york|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.|la jolla|california|united states` — added _(2026-05-12)_
- `locations.|walnut creek|california|united states` — added _(2026-05-12)_
- `locations.|jacksonville|florida|united states` — added _(2026-05-12)_
- `locations.|atlanta|georgia|united states` — added _(2026-05-12)_
- `locations.|chicago|illinois|united states` — added _(2026-05-12)_
- `locations.|lexington|kentucky|united states` — added _(2026-05-12)_
- `locations.|baltimore|maryland|united states` — added _(2026-05-12)_
- `locations.|waltham|massachusetts|united states` — added _(2026-05-12)_
- `locations.|minneapolis|minnesota|united states` — added _(2026-05-12)_
- `locations.|st louis|missouri|united states` — added _(2026-05-12)_
- `locations.|greenville|north carolina|united states` — added _(2026-05-12)_
- `locations.|dallas|texas|united states` — added _(2026-05-12)_
- `locations.|seattle|washington|united states` — added _(2026-05-12)_
- `locations.|spokane|washington|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00044148.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00044148*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*